FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910132964> ?p ?o ?g. }

• W2910132964 abstract "Background Infliximab dose is based on the patient’s body weight (3–5 mg/kg) and requires the use of multiple 100 mg vials to reconstitute the individualised dose. As the product is expensive, there is a significant cost associated with unused and wasted infliximab in any part-used vials. “Dose banding” is one solution so that patients receive a pre-prepared dose produced in advance in batches where wastage from part vials is minimised. There is some encouraging data that reconstituted infliximab is stable for long enough to allow batch production of pre-prepared doses. The theoretical risk of course is over or under treatment while respectively rounding up or down the administered dose. Objectives We undertook a retrospective analysis of our experience of dose banding in rheumatology unit. Methods All patients prescribed infliximab for rheumatic indication at our centre were included in the analysis. Case notes were retrospectively reviewed to look at dose variance following implementation of this initiative, resultant disease control and the consequent cost savings. Results 10 patients prescribed infliximab biosimilar and two bio-originator were identified for the analysis. Median age was 55.5 years (range 25–80 years). Nine had the drug for RA, two for AS and one for myositis. Three had no change in dose as a result of implementing dose banding program. Three had dose increased by 3%–5%. Remaining six had dose reduced by range of 4%–6%. Their disease scores before and after dose banding remained largely unchanged (table 1). This equated to £1,184.58 annual savings in addition to the economic benefit of successfully switching the ten patients to biosimilar. No patient suffered loss of efficacy or adverse events in any of the three groups. Conclusions Our data confirms the utility of dose banding program for infliximab in rheumatology practice with no concerns about efficacy or safety of the initiative. There are potential opportunities to achieve considerable reductions in medicines discarded and improving finances by adopting dose banding for infliximab. It also helped curb over £10 000 expense to our Trust in infliximab waste cost alone. There are some important caveats to consider as well. True savings will depend on list price of each product and varies with originator versus biosimilar. The variance increases as the width of the dose bands increases i.e. the variance is greater at lower body weights. Consequently, depending on patient population both clinical and cost considerations could alter. Finally, assurance of the product integrity and stability is reliant on efficient pharmacy processes necessary to accommodate the use of new formulations for dose banding. Disclosure of Interest None declared" @default.
• W2910132964 created "2019-01-25" @default.
• W2910132964 creator A5084718192 @default.
• W2910132964 date "2018-06-01" @default.
• W2910132964 modified "2023-09-28" @default.
• W2910132964 title "AB1259 Is dose banding of infliximab cost effective – results from real world implementation" @default.
• W2910132964 doi "https://doi.org/10.1136/annrheumdis-2018-eular.1300" @default.
• W2910132964 hasPublicationYear "2018" @default.
• W2910132964 type Work @default.
• W2910132964 sameAs 2910132964 @default.
• W2910132964 citedByCount "0" @default.
• W2910132964 crossrefType "proceedings-article" @default.
• W2910132964 hasAuthorship W2910132964A5084718192 @default.
• W2910132964 hasBestOaLocation W29101329641 @default.
• W2910132964 hasConcept C126322002 @default.
• W2910132964 hasConcept C141071460 @default.
• W2910132964 hasConcept C147789679 @default.
• W2910132964 hasConcept C185592680 @default.
• W2910132964 hasConcept C2776623344 @default.
• W2910132964 hasConcept C2777138892 @default.
• W2910132964 hasConcept C2779134260 @default.
• W2910132964 hasConcept C71924100 @default.
• W2910132964 hasConcept C72092618 @default.
• W2910132964 hasConceptScore W2910132964C126322002 @default.
• W2910132964 hasConceptScore W2910132964C141071460 @default.
• W2910132964 hasConceptScore W2910132964C147789679 @default.
• W2910132964 hasConceptScore W2910132964C185592680 @default.
• W2910132964 hasConceptScore W2910132964C2776623344 @default.
• W2910132964 hasConceptScore W2910132964C2777138892 @default.
• W2910132964 hasConceptScore W2910132964C2779134260 @default.
• W2910132964 hasConceptScore W2910132964C71924100 @default.
• W2910132964 hasConceptScore W2910132964C72092618 @default.
• W2910132964 hasLocation W29101329641 @default.
• W2910132964 hasOpenAccess W2910132964 @default.
• W2910132964 hasPrimaryLocation W29101329641 @default.
• W2910132964 hasRelatedWork W1719336872 @default.
• W2910132964 hasRelatedWork W2019219799 @default.
• W2910132964 hasRelatedWork W2021472716 @default.
• W2910132964 hasRelatedWork W2092310057 @default.
• W2910132964 hasRelatedWork W2255023026 @default.
• W2910132964 hasRelatedWork W2293590890 @default.
• W2910132964 hasRelatedWork W2327382382 @default.
• W2910132964 hasRelatedWork W2332888891 @default.
• W2910132964 hasRelatedWork W2412334351 @default.
• W2910132964 hasRelatedWork W2416288603 @default.
• W2910132964 hasRelatedWork W2542623532 @default.
• W2910132964 hasRelatedWork W2601366102 @default.
• W2910132964 hasRelatedWork W2756408095 @default.
• W2910132964 hasRelatedWork W2774233423 @default.
• W2910132964 hasRelatedWork W2799488547 @default.
• W2910132964 hasRelatedWork W2944205278 @default.
• W2910132964 hasRelatedWork W2974086575 @default.
• W2910132964 hasRelatedWork W2996212167 @default.
• W2910132964 hasRelatedWork W3006421743 @default.
• W2910132964 hasRelatedWork W3103233798 @default.
• W2910132964 isParatext "false" @default.
• W2910132964 isRetracted "false" @default.
• W2910132964 magId "2910132964" @default.
• W2910132964 workType "article" @default.